A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)

Trial Profile

A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Breast cancer; Early breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CREATE-X
  • Most Recent Events

    • 09 Jun 2017 Status changed from active, no longer recruiting to discontinued.
    • 01 Jun 2017 Primary endpoint (Disease-free survival) has been met as per the results published in the New England Journal of Medicine
    • 01 Jun 2017 Results (Data cut off date September 30, 2015), published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top